PROYECTOS ACTIVOS EN 2017 EN EL SISTEMA SANITARIO PÚBLICO VASCO ACTUALIZACIÓN: 06/11/2017
|
|
|
- Kevin Potter
- 6 years ago
- Views:
Transcription
1 1 UE/2012/DISCHARGE DIAGNOSTIC IMAGING STRATEGIES FOR CORONARY ANGIOGRAPHY IN PATIENTS WITH STABLE ANGINA: COMPARATIVE EFFECTIVENESS RESEARCH OF EXISTING TECHNOLOGIES (DISCHARGE) - A PRAGMATIC RANDOMISED CONTROLLED TRIAL 2 UE/2012/REFERENCESITE BASQUE COUNTRY - REFERENCE SITE OF THE EUROPEAN INNOVATION PARTNERSHIP ON ACTIVE AND HEALTHY AGEING (EIP AHA) AND ACTION PLANS. UNIVERSIDAD DE DEUSTO 3 UE/2012FemNAT-CD NEUROBIOLOGY AND TREATMENT OF ADOLESCENT FEMALE CONDUCT DISORDER: THE CENTRAL ROLE OF EMOTION PROCESSING 4 UE/2013/CANCON JOINT ACTION-EUROPEAN GUIDE ON QUALITY IMPROVEMENT IN COMPREHENSIVE CANCER CONTROL OSI ALTO DEBA 5 UE/2013/CAREWELL MULTI-LEVEL INTEGRATION FOR PATIENTS WITH COMPLEX NEEDS HOSPITAL SANTA MARINA OSATEK HOSPITAL ALTO DEBA 6 UE/2013/CIG THE CD300 FAMILY OF RECEPTORS IN HIV INFECTION 7 UE/2013/CHRODIS-JA JOINT ACTION ON CHRONIC DISEASES INNOVACIÓN ORGANIZATIVA Y DE GESTIÓN 8 UE/2013/ECRIN-IA PROSPECTIVE RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE BLIND, MULTICENTER STUDY (PHASE III) TO EVALUATE CLINICAL EFFICACY AND SAFETY OF AVIAN POLYCLONAL ANTI- PSEUDOMONAS ANTIBODIES (IGY) IN PREVENTION OF RECURRENCE OF PSEUDOMONAS AERUGINOSA INFECTION IN CYSTIC FIBROSIS PATIENTS A PILOT PROJECT FOR DEVELOPING AND IMPLEMENTING OSI BIDASOA 1/5
2 9 UE/2013/PRE-START 10 UE/2013/MASTERMIND A PILOT PROJECT FOR DEVELOPING AND IMPLEMENTING SUCCESSFUL PREVENTION STRATEGIES FOR TYPE 2 DIABETES OSI GOIERRI-ALTO UROLA DIRECCION GENERAL DE OSAKIDETZA OSI BIDASOA OSI BARRUALDE-GALDAKAO MANAGEMENT OF MENTAL HEALTH DISORDERS THROUGH ADVANCED TECHNOLOGY AND SERVICES - TELEHEALTH FOR THE MIND RED DE SALUD MENTAL DE BIZKAIA RED DE SALUD MENTAL DE GIPUZKOA RED DE SALUD MENTAL DE ARABA UPV/EHU HU ARABA HOSPITAL BIDASOA HOSPITAL GALDAKAO USANSOLO 11 UE/2013ANTeS ACCELERATING NEUROMUSCULAR TREATMENT SELECTION 12 UE/2015/EMERGE-JA JOINT ACTION: EFFICIENT RESPONSE TO HIGHLY DANGEROUS AND EMERGING PATHOGENS AT EU LEVEL 13 UE09/GRIP GRIP-GLOBAL RESEARCH IN PAEDIATRICS 14 UE10/NEOCIRC DOBUTAMINE FOR NEONATAL CIRCULATORY FAILURE DEFINED BY NOVEL BIOMARKERS 15 UE12/ANGELAB A NEW GENETIC LABORATORY FOR NON-INVASIVE PRENATAL DIAGNOSIS 16 UE/2015/I-MOVE-plus I-MOVE+ INTEGRATED MONITORING OF VACCINES EFFECTS IN EUROPE: A PLATFOTM TO MEASURE AND COMPARE EFFECTIVENESS AND IMPACT OF INFLUENZA AND PNEUMOCOCCAL VACCINES AND VACCINATION STRATEGIES IN THE ELDERLY 17 UE/2015/SCIROCCO SCALING INTEGRATED CARE IN CONTEXT OSATEK HU ARABA 2/5
3 18 UE/2015/ADVANTAGE-JA MANAGING FRAILTY. A COMPREHENSIVE APPROACH TO PROMOTE A DISABILITY-FREE ADVANCED AGE IN OSAKIDETZA 19 UE/2015/C3CLOUD 20 UE/2015/ACT2 A FEDERATED COLLABORATIVE CARE CURE CLOUD ARCHITECTURE FOR ADDRESSING THE NEEDS OF MULTI-MORBIDITY AND MANAGING POLY-PHARMACY ADVANCING CARE COORDINATION AND TELEHEALTH DEPLOYMENT AT SCALE OSI ALTO DEBA HOSPITAL SANTA MARINA OSI BARRUALDE-GALDAKAO HOSPITAL ALTO DEBA HOSPITAL GALDAKAO USANSOLO 21 UE/2015/STARR DECISION SUPPORT AND SELF-MANAGEMENT SYSTEM FOR STROKE SURVIVORS 22 UE/2015/SYSPHARMPEDIA SYSTEMS PHARMACOLOGY APPROACH TO DIFFICUL-TO-TREAT PEDIATRIC ASTHMA 23 UE/2015/CHRONICITY VALLEY CHRONICITY VALLEY BIOBANCO VASCO 24 UE/2015/TITTAN-INTERREG NETWORK FOR TECHNOLOGY, INNOVATION AND TRANSLATION IN AGEING 25 UE/2015/EUNETHTA-JA3 HEALTH TECHNOLOGY ASSESSMENT COOPERATION 26 UE/2015/MAGIC MOBILE ASSISTANCE FOR GROUPS & INDIVIDUALS WITHIN THE COMMUNITY - STROKE REHABILITATION (va de observador) HOSPITAL GORLIZ 27 UE/2012/HEALTH/IBD-CHARACTER IBD-CHARACTER: INFLAMMATORY BOWEL DISEASE CHARACTERIZATION 28 UE/2016/EASL EUROPEAN REGISTRY DATA COLLECTION ON CHOLANGIOCARCINOMA 29 UE/2015/PARAFISHCONTROL ADVANCED TOOLS AND RESEARCH STRATEGIES FOR PARASITE CONTROL IN EUROPEAN FARMED FISH HU ARABA - INSTITUTO BIOARABA 3/5
4 30 UE/2016/ITN/TRAIN-2 TRIBBLES RESEARCH AND INNOVATION NETWORK (BIOBANCO) 31 UE/2015/REFBIOII RED TRANSFRONTERIZA DE INVESTIGACION BIOMEDICA DE LOS PIRINEOS 2 - HACIA LA TRANSFERENCIA EFECTIVA DE RESULTAODS DE LA I+D BIOMEDICA Y SU VALORIZACION EN EL ESPACIO PIRINEOS BIOBANCO VASCO 32 UE/2016/MIDAS-BD MEANINGFUL INTEGRATION OF DATA, ANALYTICS AND SERVICES 33 UE/2016/DS/SHIELD EUROPEAN SECURITY IN HEALTH DATA EXCHANGE 34 UE/2015/ECSEL/ASTONISH 35 UE/2016/PILOTS/FLEXPOL ASTONISH- ADVANCING SMART OPTICAL IMAGING AND SENSING FOR HEALTH ANTIMICROBIAL FLEXIBLE POLYMERS FOR ITS USE IN HOSPITAL ENVIRONMENTS 36 UE/2016/EUROLINKCAT EUROLINKCAT: ESTABLISHING A LINKED EUROPEAN COHORT OF CHILDREN WITH CONGENITAL ANOMALIES 37 UE/2016/PICCOLO MULTIMODAL HIGHLY-SENSITIVE PHOTONICS ENDOSCOPE FOR IMPROVED IN-VIVO COLON CANCER DIAGNOSIS AND CLINICAL BIOBANCO VASCO 38 UE/2016/ITHACA-INTERREG INNOVATION IN HEALTH AND CARE FOR ALL 39 UE/2016/SANTE-JA/CHRODIS-PLUS CHRODIS-PLUS: IMPLEMENTING GOOD PRACTICES FRO CHRONIC DISEASES 40 UE/2016/TRANSPOSE TRANSFUSION AND TRANSPLANTATION: PROTECTION AND SELECTION OF DONORS CENTRO VASCO DE TRANSFUSIONES Y TEJIDOS HUMANOS 41 UE/2017/H2020/vCARE vcare - VIRTUAL COACHING ACTIVITIES FOR REHABILITATION IN ELDERLY / INSTITUTO BIOCRUCES 4/5
5 42 INT/2017/OBINUT MOLECULAR EFFECTS OF NUT-BASED FOOD-PRODUCTS ON CELL MEMBRANES EVALUATED BY RED BLOOD CELL LIPIDOME REMODELLING IN OBESE CHILDREN / INSTITUTO BIOCRUCES 43 UE/2016/EASL/LEE ROLE OF POSTTRANSLATIONAL MODIFICATIONS IN THE PATHOGENESIS OF POLYCYSTIC LIVER DISEASES AND THEIR POSSIBLE REGULATORY VALUE / INSTITUTO BIODONOSTIA PROYECTO FINALIZADO 5/5
For more information about the final programme, speakers or the EHFG conference please contact us directly!
For more information about the final programme, speakers or the EHFG conference please contact us directly! SAVE THE DATE! 18th EHFG: 30 September 02 October 2015 EHFG-FORUM 4 PERSONALISED MEDICINE 2020
17th EHFG Electing Health The Europe We Want!
01 03 October 2014 17th EHFG Electing Health The Europe We Want! For more information about the final programme, speakers or the EHFG conference please contact us directly! Follow us on our social media
Innovation in medical devices as response to Europe's healthcare challenges. Industry's viewpoint
HIGH-LEVEL CONFERENCE "EXPLORING INNOVATIVE HEALTHCARE THE ROLE OF MEDICAL TECHNOLOGY INNOVATION AND REGULATION" Innovation in medical devices as response to Europe's healthcare challenges Industry's viewpoint
Forthcoming Calls for Proposals (10/11) Barcelona 28 June 2013
Forthcoming Calls for Proposals (10/11) Barcelona 28 June 2013 Indicative list Proposed topic /11 /11 /11 Identification and validation of innovative clinical endpoints for Osteoarthritis European genotype-phenotype
Molecular Diagnostics
Molecular Diagnostics Part II: Regulations, Markets & Companies By Prof. K. K. Jain MD, FRACS, FFPM Jain PharmaBiotech Basel, Switzerland May 2018 A Jain PharmaBiotech Report A U T H O R ' S B I O G R
Use of RWE in a regulatory context: issues and examples. Rob Hemmings, MHRA
Use of RWE in a regulatory context: issues and examples Rob Hemmings, MHRA Disclaimer I don t particularly like the terms real world data, real world evidence. To be more precise, I will discuss data generated
The Innovative Medicines Initiative Europe s partnership for health. Tek-Ang LIM, 20 June 2018, Brussels
The Innovative Medicines Initiative Europe s partnership for health Tek-Ang LIM, 20 June 2018, Brussels 10 YEARS OF LIGHTING THE WAY IMI Why Europe s partnership for health? Because despite decades of
Clinical studies. BARBORA VLKOVÁ INSTITUTE OF MOLECULAR BIOMEDICINE
Clinical studies BARBORA VLKOVÁ INSTITUTE OF MOLECULAR BIOMEDICINE www.imbm.sk barboravlk@gmail.com Biomedical research 1. Basic research a. In vitro = cell cultures b. In vivo = experimental animals c.
Public private partnerships in support to regulatory sciences
Public private partnerships in support to regulatory sciences The Innovative Medicines Initiative example M. Chlebus 3 October 2017 www.efpia.eu Summary: Partnering on regulatory sciences Progress much
The Construction of a Clinical Trial. Lee Ann Lawson MS ARNP CCRC
The Construction of a Clinical Trial Lee Ann Lawson MS ARNP CCRC 1 Objectives Review Phases of Clinical Research Discuss Orphan Drug Act Discuss regulatory agencies Overview phases of clinical research
Topic: Genome-Environment Interactions in Inflammatory Skin Disease
Topic: Genome-Environment Interactions in Inflammatory Skin Disease All information regarding future IMI Call topics is indicative and subject to change. Final information about future IMI Calls will be
Medical Devices for The Non-Communicable Diseases Agenda Nicole Denjoy
Medical Devices for The Non-Communicable Diseases Agenda Nicole Denjoy DITTA Chair COCIR Secretary General 2 nd WHO Global Forum on Medical Devices Geneva, Switzerland Plenary session 3 on Sunday 24 November
Genes & Medicine: How DNA is Improving Your Health
Genes & Medicine: How DNA is Improving Your Health U3A Mountford, June 2004 Dr Martin Kennedy Department of Pathology Christchurch School of Medicine & Health Sciences University of Otago What this talk
HUMAN CHALLENGE TESTING
HUMAN CHALLENGE TESTING CLINICAL RESEARCH SOLUTIONS DE-RISKING Faced with increasing pressures on timelines and budgets, clinical research practices need to continuously evolve in order to ensure pipeline
Belgium, a European leader in clinical trials
Belgium, a European leader in clinical trials An attractive country for clinical trials to test innovative medicines In Europe it is nearly impossible to find other countries with as many clinical trials
Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research
Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research Drug Development Process by which new chemical entities
Classification under the IVD Regulation
Classification under the IVD Regulation Nick Baker Head of IVD Notified Body LRQA Ltd Improving performance, reducing risk IVD regulation shift in regulatory scrutiny Under the current IVD directive 10-15%
Description of Commitment
U.S. Postmarketing s Table: Name of ANDROGEL (testosterone gel) CREON (pancrelipase) CREON (pancrelipase) / 022309 and 021015 20725 20725 125057/0 Description of A randomized, double-blind, placebocontrolled
Nanotechnology and Advanced Materials for more effective Healthcare
Nanotechnology and Advanced Materials for more effective Healthcare This challenge taps into the potential of nanotechnologies and advanced materials to enable more effective therapies and diagnostics
FP7 Cooperation Work Programme: Health-2011 Topics and contact points
FP7 Cooperation Work Programme: Health-2011 Topics and contact points Date of publication: 30 July 2010 Call identifiers: Indicative budgets Deadlines FP7-HEALTH-2011-single-stage EUR 160.5 million 10
Neurodegeneration and other neuroscience priorities
Potential future IMI Call topics About this document The following topics are under consideration for inclusion in future IMI Calls for proposals in the longer term. The discussions on these topics are
May 9, Meeting Summary. Facilitating Antibacterial Drug Development
May 9, 2012 Meeting Summary Facilitating Antibacterial Drug Development Origins of the Current Public Health Crisis of Antibacterial Resistance Antibacterial drugs play a critical role in the ability to
Regulatory considerations for initiating paediatric trials with RSV antivirals
Regulatory considerations for initiating paediatric trials with RSV antivirals Irmgard Eichler European Medicines Agency Expert meeting on RSV therapeutics March 2016 An agency of the European Union In
Innovative Medicines Initiative Sadallah Fatiha IMI JU Office, Brussels, Belgium
Innovative Medicines Initiative 2 2009-2014 Sadallah Fatiha IMI JU Office, Brussels, Belgium The Evolution of IMI: From bottlenecks in industry to bottlenecks in Industry and Society Make Drug R&D processes
BIOMEDICAL RESEARCH CENTRES
Introduction BIOMEDICAL RESEARCH CENTRES The vision of the National Institute for Health Research (NIHR) is to improve the health and wealth of the nation through research. This document sets out how the
Synagis (Palivizumab) Drug Prior Authorization Protocol
Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Synagis (Palivizumab) Drug Prior Authorization Protocol This policy has been developed through review of medical
The Role of Research in Supporting Regulation of Biologicals: Building Bridges from Biomedical Discovery to Innovative Products
The Role of Research in Supporting Regulation of Biologicals: Building Bridges from Biomedical Discovery to Innovative Products Jay S. Epstein, M.D. CBER, FDA Biologicals are Complex Products Critical
Consortia-Based Strategies in Neurodegenerative Diseases: Critical Path Institute s Track Record in Collaborative Efforts
Consortia-Based Strategies in Neurodegenerative Diseases: Critical Path Institute s Track Record in Collaborative Efforts Martha A. Brumfield, PhD President & CEO Agenda C-Path Model for Collaboration
RSV Prevention in Québec Season
RSV Prevention in Québec 2017 2018 Season Marc H. Lebel, MD, FRCPC Infectious-Diseases Service Dr. Marc Lebel Pediatrician infectiologist at the Sainte Justine Hospital since 1989 Founded the infectious
Update from the Center for Biologics Evaluation and Research (CBER) Peter Marks, M.D., Ph.D. GMP By The Sea 2017
Update from the Center for Biologics Evaluation and Research (CBER) Peter Marks, M.D., Ph.D. GMP By The Sea 2017 Outline Products regulated Significance of complex biologics Product and process Cutting
ORACLE OTTAWA REGION FOR ADVANCED CARDIOVASCULAR RESEARCH EXCELLENCE STRATEGIC DIRECTIONS
ORACLE OTTAWA REGION FOR ADVANCED CARDIOVASCULAR RESEARCH EXCELLENCE STRATEGIC DIRECTIONS 2018-2024 ORACLE 2.0: Leading Globally, from Innovation to Impact P1 P2 NOTE FROM OUR LEADERS NOTE FROM VP RESEARCH,
Engage with us on Twitter: #Molecule2Miracle
Engage with us on Twitter: #Molecule2Miracle Kassy Perry President & CEO Perry Communications Group PhRMA Alliance Development Consultant.@kassyperry Emily Burke, Ph.D. Director of Curriculum BioTech
Horizon 2020 Review of Work Programme Focus on topics including Clinical Trials/Studies
Horizon 2020 Review of Work Programme 2018 2020 Focus on topics including Clinical Trials/Studies ECRIN European Correspondent Meeting Dr Sabine Klager - 08/11/2017 Health, demographic change and wellbeing
First Place Essay. Katie P.
First Place Essay Katie P. Eighth Grade West Reading, PA 19611 Bioscience research is seeking information by exploring life's processes and diseases. It has helped many scientists understand how the body
Opportunities for industry/smes in EU-funded health research
Opportunities for industry/smes in EU-funded health research Stéphane Hogan, M.Sc, MBA Head of Unit Applied Genomics and Biotechnology for Health DG Research - European Commission 1 Paris, 31 May 2005
Introduction to FI-STAR Future Internet Social and Technological Alignment Research. Anastasius Gavras Eurescom GmbH
Introduction to FI-STAR Future Internet Social and Technological Alignment Research Anastasius Gavras Eurescom GmbH gavras@eurescom.eu Trends in Healthcare More and more patients will be treated or cared
From IMI to IMI2 new models of collaborative research. Magda Chlebus, Science Policy, EFPIA Ljubljana, 23 May 2014
From IMI to IMI2 new models of collaborative research Magda Chlebus, Science Policy, EFPIA Ljubljana, 23 May 2014 What is IMI and how does it work? Innovative Medicines Initiative: Joining Forces in the
UNITING AGRICULTURE AND MEDICINE. Director, Nebraska Food for Health Center
The Nebraska Food for Health Center UNITING AGRICULTURE AND MEDICINE ANDREW K. BENSON Food for Health Presidential Chair Director, Nebraska Food for Health Center Our Food System is Driven by Production
The Role of Public-Private Partnerships & Evidence Generation
The Role of Public-Private Partnerships & Evidence Generation Christina Donatti LLB, BSc, MSc, PsyD IMI Lead, RWE EMEA Strategic Organisation. Janssen Cilag Janssen is proud to feature artwork created
LETTER OF INTENT Rapid Response: Canada 2019 Parkinson s & Related Diseases Round 2
LETTER OF INTENT Rapid Response: Canada 2019 Parkinson s & Related Diseases Round 2 DEADLINE: March 13, 2019, 2:00pm EDT Applicants will be notified of Proposal invitations in May 2019 This Letter of Intent
LETTER OF INTENT Rapid Response: Canada 2019 Parkinson s & Related Diseases Round 2
LETTER OF INTENT Rapid Response: Canada 2019 Parkinson s & Related Diseases Round 2 DEADLINE: May 15, 2019, 2:00pm EDT Applicants will be notified of Proposal invitations in August 2019 This Letter of
Gene therapy. Findings by Alert
Gene therapy Published Mar 21, 2000 Version 1 Findings by Alert Research in gene therapy has increased dramatically during the past 15 years, particularly in the United States. The research has encompassed
Agreed by IDWP and VWP September Adopted by CHMP 13 October Start of public consultation 26 October 2016
1 2 3 13 October 2016 EMA/CHMP/360458/2016 Committee for Human Medicinal Products (CHMP) 4 5 6 7 8 Concept paper on preparation of a guideline on the evaluation of medicinal products indicated for the
FDA Critical Path Initiative: Closing Productivity Gap in Medical Product Development. October 4, 2004
FDA Critical Path Initiative: Closing Productivity Gap in Medical Product Development October 4, 2004 1 What is the problem? Trends in Biomedical Research Spending R&D Spending Has Accelerated Since 1990
Pharmacy Benefit Drug Trends and Pipeline. Casey Robinson, PharmD, MBA, Cigna Pharmacy Management
Pharmacy Benefit Drug Trends and Pipeline Casey Robinson, PharmD, MBA, Cigna Pharmacy Management Disclosure and Conflict of Interest Dr. Robinson declares no conflicts of interest, real or apparent, and
Pharmacy Benefit Drug Trends and Pipeline Casey Robinson, PharmD, MBA, Cigna Pharmacy Management
Pharmacy Benefit Drug Trends and Pipeline Casey Robinson, PharmD, MBA, Cigna Pharmacy Management Disclosure and Conflict of Interest Pharmacist Objectives Dr. Robinson declares no conflicts of interest,
Principles of translational medicine: imaging, biomarker imaging, theranostics
Principles of translational medicine: imaging, biomarker imaging, theranostics Compiled by: Endre Mikus PhD, CEO Budapest, 21/9/2015 Imaging and imaging biomarkers An imaging biomarker is an anatomic,
MOSAIQUES DIAGNOSTICS
MOSAIQUES DIAGNOSTICS CLINICAL PROTEOMICS IN DRUG DEVELOPMENT INFORMATION Clinical Proteomics for early and differential diagnosis FDA Letter of Support Possibilities of a companion test in Drug Development
IMI2: Strategic research agenda and overall approach Hugh Laverty Senior Scientific Project Manager
IMI2: Strategic research agenda and overall approach Hugh Laverty Senior Scientific Project Manager Introducing IMI2: Vienna 16 July 2014 The way in which pharmaceutical companies develop new medicines
The NIHR. NIHR: health research in Professor Stephen Smye Specialty Cluster Lead, NIHR CRN, King s College London. Clinical Research Network
The NIHR NIHR: health research in 2030 Professor Stephen Smye Specialty Cluster Lead, NIHR CRN, King s College London Why? https://www.bhf.org.uk/publications/statistics/ trends-in-coronary-heart-disease-1961-2011
BACKGROUND AND PROSPECTS FOR THE FUTURE?
BACKGROUND AND PROSPECTS FOR THE FUTURE? Superbugs & Superdrugs London 5 th -6 th March 2014 R. Bax TranScrip Partners LLP Richard.Bax@transcrip-partners.com Contents 1. Background 2. Regulatory changes
Early Patient Studies in Evolution. John Horkulak Executive Director, Eurasian External Study Operations Feb 23, 2015
Early Patient Studies in Evolution John Horkulak Executive Director, Eurasian External Study Operations Feb 23, 2015 Questions How are early phase studies evolving and why the push for studying patients
Akadeemilised kliinilised uuringud kellele ja milleks? Irja Lutsar Tartu,
Akadeemilised kliinilised uuringud kellele ja milleks? Irja Lutsar Tartu, 14. 06. 2017 Doctors are men who prescribe medicines of which they know little, to cure diseases of which they know less, in human
Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development
Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development Aernout van Haarst PhD Director, European Corporate Development Feb 2016 Industry Academic Collaboration
Innovative Medicines Initiative (IMI) Future funding opportunities. Catherine Brett, IMI Conferencia H2020 y Salud Madrid, Spain 8 November 2017
Innovative Medicines Initiative (IMI) Future funding opportunities Catherine Brett, IMI Conferencia H2020 y Salud Madrid, Spain 8 November 2017 Outline What is IMI and why do we need it? How does IMI work?
Customized Phage Therapies To Eradicate Harmful Bacteria In Chronic Diseases. Europe Microbiome Congress London, 14 Nov., 2018
Customized Phage Therapies To Eradicate Harmful Bacteria In Chronic Diseases Europe Microbiome Congress London, 14 Nov., 2018 Biomx At A Glance We are a microbiome drug discovery company developing customized
Update on the IVDR. Sue Spencer
Update on the IVDR Sue Spencer Caution The new regulations are draft the principles have now been agreed but the Annexes are subject to minor changes Further details will be added later pre and post application
Drug development and evaluation with small clinical Trials from the regulatory point of view
Drug development and evaluation with small clinical Trials from the regulatory point of view Harumasa Nakamura, M.D. Deputy Review Director Office of New Drug III Pharmaceuticals and Medical Devices Agency
Report of the 2017 annual workshop of the European Network of Paediatric Research at the EMA (Enpr-EMA)
27 June 2017 EMA/320019/2017 Human Medicines Research & Development Support Division Report of the 2017 annual workshop of the European Network of Paediatric Research at the EMA (Enpr-EMA) 16 May 2017
QuantiFERON -TB Gold In-Tube:
QuantiFERON -TB Gold In-Tube: A 7-year Experience at the Bellvitge University Hospital. Dr. Miguel Santín Department of Infectious Diseases Bellvitge University Hospital University of Barcelona 2nd Symposium
Datamonitor Healthcare Pharma intelligence informa Datamonitor Healthcare Content Calendar
Datamonitor Healthcare 2017 Datamonitor Healthcare Content Calendar 2017 Content Calendar Published February 2017 Datamonitor Healthcare provides up-to-date insights and analysis that you can trust. Disease
SciTechnol Mediakit. MatheMatics. Research and Reports on. Research Journal of Clinical Pediatrics
SciTechnol Mediakit Research Journal of Clinical Pediatrics Research and Reports on MatheMatics www.scitechnol.com www.scitechnol.com Our Vision To publish, promote and disseminate the work of medical
University of Manchester and EU Funding Health & Social Care
University of Manchester and EU Funding Health & Social Care 1. FP7 Overview Facts and Figures 2. Horizon 2020 Story So Far 3. Future Activities Horizon 2020 and Beyond Claire Faichnie and Liz Fay EU Funding
Guideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (SCIg/IMIg)
23 July 2015 EMA/CHMP/BPWP/410415/2011 rev 1 Committee for Medicinal Products for Human Use (CHMP) Guideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular
Les Biomarqueurs: une composante essentielle de la Recherche Translationnelle
Les Biomarqueurs: une composante essentielle de la Recherche Translationnelle Jesús Benavides Ancien Directeur de la Recherche Maladies Neurologiques. Sanofi Ecole Doctorale Biosigne. Université Paris
Future Directions in IBD: Treatments & Approaches
Future Directions in IBD: Treatments & Approaches JASON HARPER, MD CROHN S & COLITIS FOUNDATION PATIENT EDUCATION SEMINAR MARCH 26, 2017 Outline Introduction Clinical trials: Logistics & Expectations Novel
FDA Regulation of Companion Diagnostics
FDA Regulation of Companion Diagnostics Paul Radensky October 11, 2017 Disclosure + Slideset drawn from Part I of presentation made by Janice Hogan, HoganLovells, October 2016 + Updated where appropriate
From regulation to reality challenges in translation of gene therapy and cell-based medicinal products
From regulation to reality challenges in translation of gene therapy and cell-based medicinal products Gene therapy case study: ADA-SCID Alessandro Aiuti Jonathan Appleby HSR-TIGET is focused on the implementation
Improving Population and Individual Healthcare Outcomes with Machine Learning Analytics. Lonny Northrup, Sr. Medical Informaticist
Improving Population and Individual Healthcare Outcomes with Machine Learning Analytics Lonny Northrup, Sr. Medical Informaticist 1 Intermountain Healthcare 22 hospitals 39,000 employees 850,000 members
A unique Collaborative Model for the Discovery of New Therapeutic Approaches
A unique Collaborative Model for the Discovery of New Therapeutic Approaches THE INNOVATION GAP OPEN INNOVATION TO ADDRESS THE LACK OF PRODUCTIVITY OF BIOPHARMACEUTICAL RESEARCH A PRE-COMPETITIVE PHARMA
ataluren overview A New Approach to Genetic Disorders
ataluren overview A New Approach to Genetic Disorders Ataluren Scientific Background What is ataluren? Ataluren(formerly PTC124) is the first investigational therapy with the potential to enable the formation
Hitos del Ensayo Clínico
Hitos del Ensayo Clínico Xavier Carné www.ecrin.org Insert your logo if applicable International Clinical trials day 20 May, 2013, Madrid since 2005 ECRIN hosts ICTD in one European capital Promote public
3.1 Publishable summary
3.1 Publishable summary This section must be of suitable quality to enable direct publication by the Commission. A summary description of project context and objectives, 4000 characters max The central
Charles H. Hood Foundation Child Health Research Awards Program January 2017 Award Recipients
Charles H. Hood Foundation Child Health Research Awards Program January 2017 Award Recipients Philip Kranzusch, Ph.D. Assistant Professor of Microbiology and Immunobiology Department of Cancer Immunology
Sign up to receive ATOTW weekly
RECOMBINANT HUMAN ACTIVATED PROTEIN C IN THE TREATMENT OF SEVERE SEPSIS ANAESTHESIA TUTORIAL OF THE WEEK 133 11 TH MAY 2009 Dr Richard Eve, Royal Cornwall Hospital, Cornwall, UK Correspondence to richardlloydeve@gmail.com
University Hospital Center Code: NJUH Transplant Program (Organ): Kidney Release Date: January 5, 2017 Based on Data Available: October 31, 2016
User Guide This report contains a wide range of useful information about the kidney transplant program at (NJUH). The report has three main sections: A. Program Summary B. Waiting List Information The
Biomarker Utility and Acceptance in Drug Development and Clinical Trials: an FDA Regulatory Perspective
Biomarker Utility and Acceptance in Drug Development and Clinical Trials: an FDA Regulatory Perspective Chris Leptak, MD/PhD OND Biomarker and Companion Diagnostic Lead CDER/Office of New Drugs, Immediate
ASSESSING THE EFFICACY AND SAFETY OF NORMAL INTRAVENOUS IMMUNOGLOBULIN PRODUCTS FOR MARKETING AUTHORISATIONS
ASSESSING THE EFFICACY AND SAFETY OF NORMAL INTRAVENOUS IMMUNOGLOBULIN PRODUCTS FOR MARKETING AUTHORISATIONS Guideline Title Assessing the Efficacy and Safety of Normal Intravenous Immunoglobulin Products
Guideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (SCIg/IMIg)
1 2 3 15 November 2012 EMA/CHMP/BPWP/410415/2011 rev 1 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Guideline on the clinical investigation of human normal immunoglobulin for subcutaneous
The Innovative Medicines Initiative. Pierre Meulien CNIO, Madrid - Spain
The Innovative Medicines Initiative Pierre Meulien 12.01.2017 CNIO, Madrid - Spain IMI Europe s partnership for health > 5 bn 2.5 bn Partnership 2008-2020 Pharma industry 2.5 bn EU contribution from FP7
Horizon 2020 Health Summit-IIS La Fe. Valencia, 12 de diciembre de 2017
Horizon 2020 Health Summit-IIS La Fe Valencia, 12 de diciembre de 2017 2 History 3 AsphaTeam +75 members Consultants with Life Science Background 20 team members with PhD High knowhow in drug development
Nordic Register and Biobank Data
Nordic Register and Biobank Data A basis for innovative research on health and welfare Juni Palmgren Karolinska Institutet, Stockholm Nordic conference on Real World Data Helsinki November 2016 Nordic
Aganirsen for pathological corneal neovascularisation
Aganirsen for pathological corneal neovascularisation August 2011 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
Harvard Stem Cell Institute
Welcome to the Harvard Stem Cell Institute The 1000+ scientists in the HSCI network share one goal: finding cures for human diseases. We aim to: Stimulate healing in patients by harnessing the potential
Children s health and the environment
Organised by ARTAC in partnership with ISDE and HEAL Third Paris Appeal International Congress Children s health and the environment Intensive Course in Environmental Medicine April 14, 15 and 16, 2011
Table 2. Participating Faculty Members (alphabetically by faculty member) Co-Director, Module Leader & Mentor
Michael J. Welsh, M.D. Internal Medicine (Molecular Physiology and Biophysics) Director & Paul B. McCray, M.D. Pediatrics Co-Director, Module Leader & Joseph Zabner, M.D. Internal Medicine (Institute for
Research Strategies, Trends, Opportunities in Pediatric Infectious Disease. Dr. Jaime C. Montoya, MD, MSc, PhD, CESO III Executive Director
Research Strategies, Trends, Opportunities in Pediatric Infectious Disease Dr. Jaime C. Montoya, MD, MSc, PhD, CESO III Executive Director Current state of S and T in the country Current state of research
National Health Research Institutes
National Health Research Institutes October 2008 History The founding of the National Health Research Institutes (NHRI) was first proposed in 1988 by members of Academia Sinica. In 1994 a preparatory committee
WHO Blood Regulators Network (BRN)
Distribution: General English only WHO Blood Regulators Network (BRN) Position Paper on Use of Convalescent Plasma, Serum or Immune Globulin Concentrates as an Element in Response to an Emerging Virus*
Overview of NIBIB Research Areas and Funding Opportunities. There are 27 Institutes and Centers (ICs) at the NIH NIBIB
Overview of NIBIB Research Areas and Funding Opportunities National Institute of Biomedical Imaging and Bioengineering AAPM August 2, 2016 Steven Krosnick, MD krosnics@mail.nih.gov There are 27 Institutes
Brain Tumour Australia Information FACT SHEET 22 Clinical Trials: Questions and Answers
FACT SHEET 22 Clinical Trials: Questions and Answers What is a clinical trial? Clinical trials are research studies that answer scientific questions and try to find better ways to prevent, screen for,
Introducing MN-166 Multiple Sclerosis. July 9, 2008
Introducing MN-166 A New Treatment Paradigm for Multiple Sclerosis July 9, 2008 MediciNova, Inc. 2008 Forward-Looking Statements Statements in this presentation that are not historical in nature constitute
CIBIR: Center for Biomedical Research of La Rioja Eduardo Mirpuri, PhD. Biomedical Research Coordinator
FP7 Health Partnering event 10 June 2011, Brussels International session CIBIR: Center for Biomedical Research of La Rioja Eduardo Mirpuri, PhD. Biomedical Research Coordinator Translational Research CIBIR:
The Future of Clinical and Pharmaceutical Research
The Future of Clinical and Pharmaceutical Research Petra Streng, Industry Business Unit Life Sciences, SAP AG Dr. René Fitterer, Public Services & Healthcare, SAP (Switzerland) Inc. SAP Forum Basel, 20
Plataformas de apoyo a la investigación: biobancos y centros de recursos biológicos
Plataformas de apoyo a la investigación: biobancos y centros de recursos biológicos Jornadas: La realidad de los biobancos a la luz del nuevo marco normativo: retos e implicaciones Centro de Investigación
Towards a P4 Healthcare System: Predictive, Preventive, Personalized & Participatory
Towards a P4 Healthcare System: Predictive, Preventive, Personalized & Participatory Bull, 2012 Natalia Jiménez Lozano Business Development Manager BULL e-health Consultancy & Business Solutions Tlf: 913939253
8. Clinical Trial Assessment Phase II
8. Clinical Trial Assessment Phase II Junko Sato, PhD Office of New Drug I, PMDA Disclaimer: The information within this presentation is based on the presenter s expertise and experience, and represents
A European Public-Private Partnership! in Healthcare! Michel Goldman, MD,PhD Executive Director
A European Public-Private Partnership! in Healthcare! Michel Goldman, MD,PhD Executive Director ITMAT 2010, 27 October 2010 EFPIA Member Companies Participating companies (September 2010):! Innovative
MRC Funding for Translational Research
MRC Funding for Translational Research Dr Tom Foulkes tom.foulkes@headoffice.mrc.ac.uk May 2011 Translational research - importance to the MRC Central to delivery of MRC s mission Recent favourable CSR
Framework for FDA s Real-World Evidence Program
Framework for FDA s Real-World Evidence Program Jacqueline Corrigan-Curay, J.D., M.D. Director, Office of Medical Policy Center for Drug Evaluation and Research Food and Drug Administration March 15, 2019